Oculis Holding AG (OCS)
| Previous close | 11.75 |
| Open | 12.00 |
| Bid | 11.90 x 1000 |
| Ask | 11.99 x 1100 |
| Day's range | 11.80 - 12.00 |
| 52-week range | 6.26 - 14.50 |
| Volume | |
| Avg. volume | 18,049 |
| Market cap | 436.496M |
| Beta (5Y monthly) | 0.16 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.68 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 32.29 |
GlobeNewswireOculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNFα Licaminlimab (OCS-02) in Dry Eye Disease
Licaminlimab is a novel anti-TNFα biologic eye drop with an established dual mechanism of action, anti-inflammatory and anti-apoptotic, and a potential transformative impact on the treatment of inflammatory eye diseasesRELIEF Phase 2b trial will evaluate the efficacy and safety of licaminlimab in moderate-to-severe Dry Eye Disease, and further explore the potential of a genetic biomarkerTrial was initiated as planned with topline results expected in mid-2024 ZUG, Switzerland and BOSTON, Dec. 07,
Simply Wall St.Oculis Holding AG's (NASDAQ:OCS) top owners are individual investors with 48% stake, while 30% is held by private equity firms
Key Insights Oculis Holding's significant individual investors ownership suggests that the key decisions are influenced...
GlobeNewswireOculis Reports Q3 2023 Financial Results and Provides Company Update
Reported lead product candidate OCS-01 eye drop met both primary endpoints in Phase 3 OPTIMIZE trial for inflammation and pain after cataract surgery following positive readout of Stage 1 of the Phase 3 DIAMOND trial for diabetic macular edema (DME)Enrolled first patient in the investigator-initiated LEOPARD trial evaluating OCS-01 for treatment of cystoid macular edema (CME)Cash and investments of $116.5 million adequately funded to deliver on key business and clinical milestones ZUG, Switzerla
